Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Will T-cell therapy for cancer ever be a standard of care?

Abstract

Cellular therapies for cancer are showing increasing efficacy but their introduction as a ‘standard of care’ for these disorders is hampered by technical, regulatory and financial concerns. This review identifies some of the major problems and suggests potential solutions.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Cheever MA, Higano CS . PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17: 3520–3526.

    Article  PubMed  Google Scholar 

  2. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535–546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126–129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925–935.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264–1270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007; 110: 2838–2845.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698–2703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010; 115: 3869–3878.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous epstein-barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005; 23: 8942–8949.

    Article  CAS  PubMed  Google Scholar 

  11. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010; 33: 983–990.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Blazar BR, Murphy WJ, Abedi M . Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443–458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550–4557.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C . White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 2011; 17: 1664–1673.

    Article  CAS  PubMed  Google Scholar 

  15. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118: 6050–6056.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Heslop H . Getting personal with melanoma. Clin Cancer Res 2011; 17: 4189–4191.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M . Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002; 20: 70–75.

    Article  CAS  PubMed  Google Scholar 

  18. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121: 1822–1826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bollard CM, Rossig C, Calonge MJ, Huls MH, Wagner HJ, Massague J et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002; 99: 3179–3187.

    Article  CAS  PubMed  Google Scholar 

  20. Riviere I, Dunbar CE, Sadelain M . Hematopoietic stem cell engineering at a crossroads. Blood 2012; 119: 1107–1116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ et al. CARs on track in the clinic. Mol Ther 2011; 19: 432–438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sadelain M, Brentjens R, Riviere I . The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215–223.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Jorritsma A, Schotte R, Coccoris M, de Witte MA, Schumacher TN . Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther 2011; 11: 276–287.

    Article  CAS  PubMed  Google Scholar 

  24. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010; 33: 305–315.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther 2011; 19: 2258–2268.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH et al. Most closely HLA-matched allogeneic virus specific cytotoxic T-lymphocytes (CTL) to treat persistent reactivation or infection with adenovirus, CMV and EBV after hemopoietic stem cell transplantation (HSCT). Blood 2010; 117 (Suppl 1): 829.

    Google Scholar 

  27. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy 2010; 12: 743–749.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 2011; 117: 788–797.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19: 620–626.

    Article  CAS  PubMed  Google Scholar 

  30. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843–851.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M . Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010; 18: 666–668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Heslop HE . Safer CARS. Mol Ther 2010; 18: 661–662.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489–500.

    Article  PubMed  Google Scholar 

  34. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105: 4247–4254.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365: 1673–1683.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M K Brenner.

Ethics declarations

Competing interests

The author is a scientific advisory board member of Jennerex and of BluebirdBio. The Author’s spouse is a scientific advisory board member for CellMedica. Some of the approaches described in this article are licensed by CAGT investigators to commercial entities (CellMedica, Bellicum).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brenner, M. Will T-cell therapy for cancer ever be a standard of care?. Cancer Gene Ther 19, 818–821 (2012). https://doi.org/10.1038/cgt.2012.74

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2012.74

Keywords

This article is cited by

Search

Quick links